Open AccessAn Innovative Site-Specific Anti-HER2 Antibody-Drug Conjugate with High Homogeneity and Improved Therapeutic Index
Author(s) -
Xiwu Hui,
Can Yuan,
Weirong Cao,
Wenli Ge,
Di Zhang,
Mo Dan,
Qian Zhao,
Boning Liu,
Bing Yao
Publication year - 2022
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s357326
Subject(s) - in vivo , antibody drug conjugate , cytotoxicity , in vitro , conjugate , antibody , antibody dependent cell mediated cytotoxicity , chemistry , therapeutic index , pharmacology , monoclonal antibody , drug , medicine , biochemistry , immunology , biology , mathematical analysis , microbiology and biotechnology , mathematics
Antibody-drug conjugates (ADCs) have emerged as a potent cancer therapeutic option in recent years. DP303c is a HER2-targeting ADC with a cleavable linker-MMAE payload. The current study aimed to evaluate the therapeutic potentials of DP303c in vitro as well as in vivo.